| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 12 | 624 | ||
| Accounts receivable | 15 | - | ||
| Inventory | 485 | 486 | ||
| Current portion of notes receivable | 199 | 200 | ||
| Prepaid expenses and other current assets | 206 | 171 | ||
| Total current assets | 917 | 1,481 | ||
| Property, plant and equipment, net | 13 | 14 | ||
| Other intangible assets, net | 17,278 | 17,565 | ||
| Notes receivable | - | 0 | ||
| Total assets | 18,208 | 19,060 | ||
| Accounts payable | 576 | 554 | ||
| Accrued expenses | 336 | 266 | ||
| Note payable, related party | 22,881 | 22,352 | ||
| Total current liabilities | 23,793 | 23,172 | ||
| Deferred tax liability, net | 3,268 | 3,268 | ||
| Total liabilities | 27,061 | 26,440 | ||
| Preferred stock, 0.001 par value 100,000,000 shares authorized, 60,496,041 shares issued and outstanding (60,496,041 on december 31, 2024) liquidation value 0.001 per share, 60,496,041 aggregate. 60,496,041 on december 31, 2024) | 60 | 60 | ||
| Common stock, 0.001 par value 4,000,000,000 shares authorized, 12,185,412 shares issued and outstanding (11,503,955 on december 31, 2024) | 12 | 12 | ||
| Additional paid-in capital | 42,871 | 42,870 | ||
| Accumulated deficit | -54,752 | -53,283 | ||
| Total stockholders (deficit) equity of the company | -11,809 | -10,341 | ||
| Non-controlling interest in subsidiaries | 2,956 | 2,961 | ||
| Total stockholders (deficit) equity | -8,853 | -7,380 | ||
| Total liabilities and stockholders (deficit) equity | 18,208 | 19,060 | ||
IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC. (IBO)